Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Recruiting · NCT07064330 · Registry updated 2025-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab. | Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | Not stated | 2025-09-10 | NCT07064330 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Carlos III Health Institute | 18 |
| Instituto de Investigación Biomédica de Salamanca | 22 |
| Regeneron Pharmaceuticals | 238 |
| University of Salamanca | 40 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Complejo Asistencial Universitario de Salamanca | Salamanca | Spain | 7 |